Keiko Ihara

Keiko Ihara

Auto-generated profile, based on publicly available information

Keiko Ihara

Department of Neurology, Keio University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2023 in Journal of the Neurological Sciences
Verified
Journal Article
Open access
KIKeiko Ihara
Keiko Ihara
SOSeiya Ohtani
Seiya Ohtani
NWNarumi Watanabe
Narumi Watanabe
Nobuyuki TakahashiNobuyuki Takahashi
Nobuyuki Takahashi
NMNaoki Miyazaki
Naoki Miyazaki
TTTsubasa Takizawa
Tsubasa Takizawa
Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) have dramatically changed preventive treatment options for patients with migraine. Although there is emerging real-world evidence on the use of CGRPmAbs globally, the change in efficacy and safety after switching between CGRPmAbs owing to patients' frequency of hospital visits preference remains unknown. We conducted a single-centre, retrospective, real-world study of patients with migraine who first received galcanezumab for 3 or 4 months and then switched to fremanezumab at Keio University Hospital. We investigated changes in monthly migraine days (MMD), responder rate, and adverse effects such as injection site reactions. MMD increased only by 0.7 (95% CI, -4.1-5.5; p = 0.748) after 4 months of treatment with fremanezumab (6.1, 95% CI, 2.3-9.9) compared to before switching (5.4, 95% CI, 2.2-8.6). Furthermore, switching from galcanezumab to fremanezumab produced only minor adverse events, such as injection site reactions. After switching from galcanezumab to fremanezumab out of the desire to visit the hospital less often, the reduction in MMD compared to baseline was sustained, and no serious adverse effects were observed.

8 July 2024 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
KIKeiko Ihara
Keiko Ihara
GDGina Dumkrieger
Gina Dumkrieger
PZPengfei Zhang
Pengfei Zhang
TTTsubasa Takizawa
Tsubasa Takizawa
TSTodd J. Schwedt
Todd J. Schwedt
CCChia-Chun Chiang
Chia-Chun Chiang

16 May 2022 in Computers in Biology and Medicine
Verified
Journal Article
Open access
AMAyako Maeda-Minami
Ayako Maeda-Minami
KIKeiko Ihara
Keiko Ihara
TYTetsuhiro Yoshino
Tetsuhiro Yoshino
YHYuko Horiba
Yuko Horiba
MMMasaru Mimura
Masaru Mimura
KWKenji Watanabe
Kenji Watanabe
Objective: To establish a prediction model of qi stagnation referring to two existing models.Design: Prospective observational study.Setting: We recruited patients who visited the Kampo Clinic at Keio University from February 2011 to March 2013.Methods: We constructed a random forest algorithm with 202 items as independent variables to predict qi stagnation patterns using full agreement data of the physicians' diagnosis and the result of two existing scores as a reference standard. To compare the new model with the two existing models, we calculated the discriminant ratio (prediction accuracy), precision, sensitivity (recall), specificity, and F-measure of these models.Results: The number of eligible participants was 1,194, and 29.1% of them were diagnosed with qi stagnation by Kampo physicians. The discriminant ratio, precision, sensitivity, specificity, and F-measure in our new model were 0.960, 0.672, 0.911, 0.964, and 0.774, respectively. Our new model had a significantly higher discriminant ratio than the two existing models.Conclusions: We constructed a better qi stagnation prediction model than the previously established ones. Our results can be utilized to reach an international agreement on qi stagnation pattern diagnosis in traditional East Asian medicine.


17 December 2025 in Cephalalgia
Verified
Journal Article
Open access
KIKeiko Ihara
Keiko Ihara
CPC. William Pike
C. William Pike
GHGavin Hui
Gavin Hui
SGSaurabh Gombar
Saurabh Gombar
MJMichael L. Jackson
Michael L. Jackson
CCChia-Chun Chiang
Chia-Chun Chiang
Background: Many guidelines list migraine with aura (MwA) as a contraindication to estrogen-containing combined hormonal contraceptives (CHCs) due to vascular risks. However, current evidence is based on small sample studies with potential influence by confounding factors. Additionally, few studies have examined the vascular risk associated with modern CHCs with lower dose estrogen, particularly in relation to aura status. The present study aims to investigate the vascular risk of modern CHCs in women with migraine with and without aura. Methods: We used a de-identified electronic medical record database with 120 million patients across multiple health systems in the United States of America. We included female patients aged 18–45 years who received a migraine diagnosis code, had at least three office visits within three years, and were prescribed at least one migraine-specific medication within 6 months following the first outpatient visit. All data after 2010 were included. Patients with prior cardiovascular events were excluded. Our composite endpoint consisted of acute ischemic stroke, acute myocardial infarction, deep vein thrombosis/pulmonary embolism and intravenous thrombolytic administration. We stratified our analysis according to CHC exposure and aura status and compared the incidence of the endpoint with high-dimensional propensity score-matching between CHC users and non-users in (i) the overall cohort, (ii) MwA and (iii) migraine without aura (MwoA); between MwA and MwoA in (iv) patients prescribed CHCs; and in (v) those without CHC prescriptions. Results: We included 5535 patients who received CHC prescriptions and 21,520 who did not. 114 (2.06%) of CHC users and 547 (2.54%) of CHC non-users had at least one vascular event. With propensity score-matched comparison, the composite endpoint did not significantly differ between CHC and non-CHC in the overall migraine group, those with MwA and the MwoA group. In those prescribed CHC, MwA and MwoA did not differ in all the outcomes. For CHC non-users, MwA was associated with a higher incidence of acute ischemic stroke (hazard ratio = 2.45; 95% confidence interval = 1.58–3.78; p < 0.001; n = 6201 in each group) and the composite endpoint (hazard ratio = 1.34; 95% confidence interval = 1.08–1.67; p = 0.008). Conclusions: Our real-world study showed that exposure to modern CHC was not associated with a significant increase in vascular risk in women aged 18–45 years with migraine, MwA or MwoA who have no prior cardiovascular events. However, in those who never received CHC, MwA was associated with higher vascular risks compared to MwoA. While limitations exist using large scale electronic medical record databases for analysis, our results suggest that carefully designed prospective studies should be conducted to reassess the vascular risk associated with CHC use in women with migraine, especially MwA.

17 November 2026 in Cephalalgia
Verified
Journal Article
Open access
KIKeiko Ihara
Keiko Ihara
CCChia-Chun Chiang
Chia-Chun Chiang
PYPing-Hao Yang
Ping-Hao Yang
CCChieh-Ju Chao
Chieh-Ju Chao
FLFrancisco Lopez-Jimenez
Francisco Lopez-Jimenez
NZNan Zhang
Nan Zhang
Aim: Patients with migraine, especially those with aura, have a higher risk of stroke and other vascular events. However, the underlying mechanisms are complex, multifactorial, and may require integration of multimodal data for comprehensive characterization. We have conducted prior analyses on how artificial intelligence (AI)-enabled electrocardiogram (ECG), specifically the atrial fibrillation prediction model and age estimation model output, echocardiogram parameters, and detailed migraine characteristics separately predict vascular events. Herein, we aim to investigate the relative importance and combined effects of all three modalities for vascular risk prediction. Methods: In this retrospective cohort study, we developed a multimodality prediction risk score to evaluate the vascular risks in patients with migraine based on the coefficients of variables extracted from our prior studies, including comprehensive AI-ECG atrial fibrillation prediction model output and computed delta age (ECG estimated age minus chronological age), echocardiogram parameters, and migraine characteristics. We then included patients with at least one 12-lead ECG, transthoracic echocardiogram, and a visit with a headache specialist at any Mayo Clinic site within three years to evaluate the risk score. The outcome is a composite endpoint of acute ischemic stroke, acute myocardial infarction, venous thromboembolism, and all-cause mortality. We selected 20 risk parameters, including demographics, comorbidities, AI-ECG outputs, echocardiogram features, and migraine characteristics found to be predictive of vascular events. Each variable was assigned a different risk score according to the hazard ratio (HR) and beta coefficient from prior Cox regression analysis for each modality. We used Contal and Q’Quigley's method to find the optimal cut-off, and an additional multivariate Cox regression was conducted to assess the relative risk of each parameter category in the final cohort. We investigated the added value of each modality by net reclassification improvement rate. Results: A total of 29,928 patients, 12,778 patients, and 6819 patients were included to investigate how AI-ECG outputs, echocardiogram parameters, and migraine characteristics, respectively, predicted adverse vascular outcomes, and the results were used to develop a multimodal risk score. A total of 297 patients with migraine included in previous analyses, of whom 247 (83.2%) were female and 109 (36.7%) had aura, were used for proof-of-concept evaluation of the developed risk score. The mean (standard deviation, SD) age was 39.0 (13.3) and follow-up period was 68.9 (60.9) months. Thirty-five patients (11.8%) developed the composite endpoint. Those with a risk score ≥15 had a significantly shorter vascular event-free survival (HR [95% Confidence Interval (CI)], 3.83 [1.89–7.76]; p < 0.001) compared to those with a risk score <15 in our cohort of 297 patients. Furthermore, comorbidity (HR, 1.17 [1.06–1.30]; p = 0.003) and migraine characteristics (HR, 1.33 [1.06–1.67]; p = 0.014) were significantly predictive of the composite endpoint, whereas other categories were not. Net reclassification improvement was 17.7% (95% CI, 15.9−19.9%; p < 0.001) for AI-ECG model output, 16.9% (95% CI, 14.1−19.5%; p < 0.001) for echocardiogram, and 22.1% (95% CI, 16.7−26.9%; p < 0.001) for migraine characteristics, suggesting significant contribution from each modality. Conclusion: This pilot evaluation study supports the use of combined AI-ECG output, echocardiogram, and migraine characteristics for vascular risk prediction. Although future external validation and real-world clinical assessment is necessary, our preliminary results suggest significant added value of each modality and indicate the importance of obtaining detailed migraine features for vascular risk stratification.